Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.59 |
| ▸ | CDC7 | O00311 | 2/20 | 0.58 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | RARG | P13631 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27729658 | 0.89 | NTRK1 (0.59) | NTRK1CDC7DBF4SMN1; SMN2ALDH1A1 | |
| SCHEMBL1398786 | 0.88 | GAA (0.57) | NTRK1CDC7DBF4SMN1; SMN2ALDH1A1 | |
| SCHEMBL956697 | 0.88 | CDC7 (0.61) | NTRK1CDC7DBF4SMN1; SMN2ALDH1A1 | |
| SCHEMBL10242392 | 0.88 | KMT2A (0.58) | NTRK1CDC7DBF4SMN1; SMN2ALDH1A1 | |
| SCHEMBL13494028 | 0.86 | CDC7 (0.63) | NTRK1CDC7DBF4SMN1; SMN2CCNE1 | |
| SCHEMBL13494131 | 0.86 | RARA (0.54) | NTRK1CDC7DBF4SMN1; SMN2ALDH1A1 | |
| SCHEMBL1398685 | 0.85 | MAPK14 (0.52) | NTRK1CDC7DBF4SMN1; SMN2ALDH1A1 | |
| SCHEMBL10242397 | 0.85 | ADORA3 (0.61) | NTRK1SMN1; SMN2ALDH1A1ALOX5HTT | |
| SCHEMBL1398715 | 0.85 | PTGDR2 (0.62) | NTRK1CDC7DBF4SMN1; SMN2ALDH1A1 | |
| SCHEMBL1339569 | 0.85 | PTGS2 (0.54) | NTRK1CDC7DBF4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-107074808-B | Therapeutic compounds as orexin-1 receptor inhibitors | 希四克斯探索有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| EP-3189043-B1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| WO-2006085815-A1 | THIAZOLE DERIVATIVES, THEIR PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | WO | disclosed |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| CN-1153172-A | Azole derivatives, their use, production and usage | NIHON NOHYAKU CO LTD (JP) | 1997-07-02 | — | — | CN | disclosed |
| EP-0761658-A1 | Azole-phenyl urea derivatives as ACAT inhibitors and their production | NIHON NOHYAKU CO., LTD. (JP) | 1997-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | NTRK1 3553/4885CDC7 2949/4885DBF4 4356/4885 |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AHR, ARNT, MYC | NTRK1 1693/4885CDC7 1896/4885DBF4 1889/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | NTRK1 4163/4885CDC7 2461/4885DBF4 4299/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | NTRK1 3836/4885CDC7 4721/4885DBF4 4331/4885 |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | NTRK1 895/4885CDC7 3825/4885DBF4 4722/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | NTRK1 3553/4885CDC7 2949/4885DBF4 4356/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | NTRK1 3553/4885CDC7 2949/4885DBF4 4356/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | NTRK1 2171/4885CDC7 4640/4885DBF4 4155/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | NTRK1 3842/4885CDC7 4721/4885DBF4 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.